{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04117074",
            "orgStudyIdInfo": {
                "id": "J17157"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB00223229",
                    "type": "OTHER",
                    "domain": "JHM IRB"
                }
            ],
            "organization": {
                "fullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "briefTitle": "Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery",
            "officialTitle": "A Non-Inferiority Randomized Trial Comparing the Impact of Thoracic Epidural Analgesia Versus Surgical Site Infiltration With Liposomal Bupivicaine on the Postoperative Recovery of Patients Following Open Gynecologic Surgery",
            "therapeuticArea": [
                "Other"
            ],
            "study": "thoracic-epidural-analgesia-vs-surgical-site-infiltration-with-liposomal-bupivacaine-following-open-gynecologic-surgery"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-04-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-10-03",
            "studyFirstSubmitQcDate": "2019-10-03",
            "studyFirstPostDateStruct": {
                "date": "2019-10-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Pacira Pharmaceuticals, Inc",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to test the hypothesis that surgical site infiltration with liposomal bupivacaine (LB) is non-inferior to and more cost effective than thoracic epidural analgesia (TEA) for patients undergoing open gynecologic surgery on an established enhanced recovery program (ERP) using a non-inferiority randomized trial design. The impact of TEA and surgical site infiltration with LB on neuroendocrine and inflammatory mediators of surgical stress response (SSR) will also be investigated as a translational endpoint."
        },
        "conditionsModule": {
            "conditions": [
                "Surgery",
                "Analgesia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1: Thoracic Epidural Analgesia with bupivicaine",
                    "type": "EXPERIMENTAL",
                    "description": "Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \\[mL\\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.",
                    "interventionNames": [
                        "Other: Thoracic epidural analgesia (bupivacaine)"
                    ]
                },
                {
                    "label": "Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine",
                    "type": "EXPERIMENTAL",
                    "description": "Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.",
                    "interventionNames": [
                        "Drug: Liposomal bupivacaine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Liposomal bupivacaine",
                    "description": "Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.",
                    "armGroupLabels": [
                        "Arm 2: Surgical Site Infiltration with Liposomal Bupivacaine"
                    ],
                    "otherNames": [
                        "Exparel"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Thoracic epidural analgesia (bupivacaine)",
                    "description": "Perioperative bupivacaine based thoracic epidural placed preoperatively.",
                    "armGroupLabels": [
                        "Arm 1: Thoracic Epidural Analgesia with bupivicaine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Analgesia as assessed by pain intensity scores on a visual analog scale",
                    "description": "Pain intensity will be measured using visual analog scale (VAS) pain intensity scores. The VAS scores pain intensity on a scale of 0-10, where 0 is no pain and 10 is the most severe pain.",
                    "timeFrame": "0 to 48 hours postoperatively"
                },
                {
                    "measure": "Total opioid consumption",
                    "description": "Total opioid consumption in IV mg morphine equivalents from 0 to 48 hours postoperatively will be compared between the two arms.",
                    "timeFrame": "0 to 48 hours postoperatively"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Patient-perceived quality of recovery as assessed by the Quality of Recovery-15 instrument (QoR-15)",
                    "description": "Mean patient-perceived quality of recovery scores using the Quality of Recovery-15 instrument (QoR-15) on postoperative days 1 to 7 will be compared between the two arms. The QoR-15 is a validated instrument designed to measure the major domains of postoperative recovery including functional independence, physical comfort/pain, psychological/emotional well-being, cognition and satisfaction with a score of 0 indicating the poorest patient-perceived quality of recovery and 150 indicating the highest patient-perceived quality of recovery.",
                    "timeFrame": "Days 1 through 7 post-intervention"
                },
                {
                    "measure": "Time (days) to return of bowel function (ROBF)",
                    "description": "Time to ROBF is defined as the time lapse from the day of surgery (DOS) to the day oral intake is consistently tolerated for 48 hours without vomiting.",
                    "timeFrame": "Up to 7 days post-intervention"
                },
                {
                    "measure": "Number of participants with postoperative ileus",
                    "description": "Ileus is defined as the occurrence of postoperative nausea and vomiting requiring cessation of oral intake and initiation of intravenous hydration +/- nasogastric tube placement following documented ROBF or the persistence of these symptoms beyond postoperative day 5 in the absence of ROBF.",
                    "timeFrame": "Up to 7 days post-intervention"
                },
                {
                    "measure": "Mobility as assessed by the Johns Hopkins Highest Level of Mobility (JH-HLM) scale",
                    "description": "The Johns Hopkins Highest Level of Mobility scale is an ordinal scale from 1 to 8, with numbers representing mobility milestones that patients accomplish, based on observation. Patients who score a 2 have some type of bed mobility, while those scoring an 8 can walk more than 250 feet.",
                    "timeFrame": "Up to 7 days post-intervention"
                },
                {
                    "measure": "Degree of sedation as assessed by the Pasero Opioid-Induced Sedation Scale",
                    "description": "The Pasero Opioid-induced Sedation Scale (POSS) is a valid, reliable tool used to assess sedation when administering opioid medications to manage pain. It uses an ordinal scale of 1-4 with a POSS of 1 or 2 indicating an acceptable level of sedation and a score of 3 or 4 indicating over-sedation and the need for intervention, such as the administration of a reversal agent in the case of a score of 4.",
                    "timeFrame": "Up to 7 days post-intervention"
                },
                {
                    "measure": "Length of stay",
                    "description": "The duration of the index inpatient postoperative admission in days.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Time to postoperative diuresis",
                    "description": "Time to diuresis is defined as the recovery time in hours to achieve a net negative fluid balance sustained over a 24 hour time period.",
                    "timeFrame": "Arrival in recovery through hospital discharge, up to 1 year"
                },
                {
                    "measure": "Total intravenous fluids administered in mL",
                    "timeFrame": "Arrival in recovery through hospital discharge, up to 1 year"
                },
                {
                    "measure": "Amount of Vasopressor required",
                    "description": "Total amount (micrograms) of vasopressor required.",
                    "timeFrame": "Start of operation through hospital discharge, up to 1 year"
                },
                {
                    "measure": "Duration of Vasopressor administration",
                    "description": "Duration (minutes) of vasopressor administration.",
                    "timeFrame": "Start of operation through hospital discharge, up to 1 year"
                },
                {
                    "measure": "Number of postoperative complications",
                    "description": "Number of postoperative complications (Maryland Hospital Acquired Conditions).",
                    "timeFrame": "Day of admission through postoperative day 30"
                },
                {
                    "measure": "Total direct cost of TEA placement and LB surgical site infiltration",
                    "description": "Pharmacy and equipment costs, professional fees and the dollar-value of total OR time required for administration of each intervention will be compared.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Post-discharge narcotic utilization",
                    "description": "Patient reported total outpatient narcotic use in IV morphine (mg) equivalents on nurse phone survey administered on postoperative day 14.",
                    "timeFrame": "Postoperative day 14"
                },
                {
                    "measure": "Change in Serum adrenocorticotropic hormone (ACTH)",
                    "description": "Serum ACTH level in pg/mL.",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Epinephrine level (pg/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Total cortisol level (microgram/dL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Anti-diuretic hormone (ADH) level",
                    "description": "ADH level in pg/mL.",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Interleukin-6 level (pg/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Atrial natriuretic peptide (ANP) level",
                    "description": "ANP level in pg/mL.",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Syndecan-1 level (pg/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Glycosaminoglycans level (ng/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Endothelial glycocalyx constituents (ng/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in C-reactive protein level (ng/mL)",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Tumor necrosis factor alpha (TNF-\u03b1) level",
                    "description": "TNF-\u03b1 level in pg/mL.",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Change in Salivary cortisol (microgram/dL) level",
                    "timeFrame": "Baseline and postoperative day 7"
                },
                {
                    "measure": "Rate of 30-day hospital readmission",
                    "description": "Rate of 30-day hospital readmission assessed as the number of participants who get readmitted within 30 days of discharge from the initial admission.",
                    "timeFrame": "Up to 30 days post discharge from index admission"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals \u2265 18 years of age\n* Planned laparotomy by the gynecologic oncology service at the sponsor institution.\n\nExclusion Criteria:\n\n* Individuals who have a contraindication to thoracic epidural analgesia\n* Individuals with a coagulation disorder\n* Individuals with an infection at the site of epidural placement\n* Individuals with intracranial pathology such as non-communicating increased intracranial pressure or obstruction of cerebrospinal fluid flow related to mass lesions\n* Individuals with spinal pathology: abnormal spine anatomy, surgical fusion, or spinal column lesions\n* Individuals who have a contraindication to liposomal bupivacaine\n* Individuals with a known allergic reaction to liposomal bupivacaine\n* Individuals with Childs-Pugh Class B or C liver disease\n* Individuals who have a history of long-term opioid use for chronic pain, defined as use of opioid pain medications for \u22654 weeks prior to surgery.",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rebecca L Stone, MD",
                    "role": "CONTACT",
                    "phone": "410-955-8240",
                    "email": "rstone15@jhmi.edu"
                },
                {
                    "name": "Amanda Fader, MD",
                    "role": "CONTACT",
                    "phone": "410-955-8240",
                    "email": "afader1@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rebecca L Stone, MD",
                    "affiliation": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Johns Hopkins Hospital",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21287",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rebecca L Stone, MD",
                            "role": "CONTACT",
                            "phone": "410-955-8240",
                            "email": "rstone15@jhmi.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000377",
                    "term": "Agnosia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010468",
                    "term": "Perceptual Disorders"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3727",
                    "name": "Agnosia",
                    "asFound": "Analgesia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13379",
                    "name": "Perceptual Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T241",
                    "name": "Agnosia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002045",
                    "term": "Bupivacaine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000779",
                    "term": "Anesthetics, Local"
                },
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M5315",
                    "name": "Bupivacaine",
                    "asFound": "Type",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M4109",
                    "name": "Anesthetics, Local",
                    "relevance": "LOW"
                },
                {
                    "id": "T312",
                    "name": "Tea",
                    "asFound": "Knee Prosthesis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}